Wang, Yu-HungYu-HungWangCHI-YUAN YAOCHIEN-CHIN LINGurashi, KristianKristianGurashiAmaral, Fabio M RFabio M RAmaralBossenbroek, HasseHasseBossenbroekJerez, AndresAndresJerezSomervaille, Tim C PTim C PSomervailleBinder, MoritzMoritzBinderPatnaik, Mrinal MMrinal MPatnaikHSIN-AN HOUWEN-CHIEN CHOUBatta, KiranKiranBattaWiseman, Daniel HDaniel HWisemanHWEI-FANG TIEN2023-02-152023-02-152023-02-0600071048https://scholars.lib.ntu.edu.tw/handle/123456789/628107Leukaemic stem cell (LSC) gene expression has recently been linked to prognosis in patients with acute myeloid leukaemia (17-gene LSC score, LSC-17) and myelodysplastic syndromes. Although chronic myelomonocytic leukaemia (CMML) is regarded as a stem cell disorder, the clinical and biological impact of LSCs on CMML patients remains elusive. Making use of multiple independent validation cohorts, we here describe a concise three-gene expression signature (LSC-3, derived from the LSC-17 score) as an independent and robust prognostic factor for leukaemia-free and overall survival in CMML. We propose that LSC-3 could be used to supplement existing risk stratification systems, to improve prognostic performance and guide management decisions.enchronic myelomonocytic leukaemia; leukaemia stem cell; prognostic scoring system[SDGs]SDG3journal article10.1111/bjh.18681367464312-s2.0-85147495122https://api.elsevier.com/content/abstract/scopus_id/85147495122